Browse News
Filter News
Found 3,565 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Cancer Gene Therapy Industry is Rising Rapidly Up to USD 18.11 Bn by 2033
4/18/2024
The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033
-
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
4/16/2024
Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/16/2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
-
Colossal Announces Expansion of Ancient DNA Academic Research Projects with $7.5M in New Investments, and Issues Call to Researchers
4/15/2024
Colossal today announces progress on its ancient DNA agenda and a go-forward vision to enable critical new discoveries from ancient DNA through its academic partners that may prove invaluable to how we navigate our changing climate.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
4/11/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference.
-
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
4/11/2024
Macomics Ltd, a leader in macrophage drug discovery, has unveiled details of its lead programme, a first-in-class ligand independent-pan-LILRB monoclonal antibody for the treatment of cancer, having presented key data on MACO-355 at the American Association for Cancer Research Annual Meeting in San Diego1.
-
Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board
4/10/2024
Nodexus Inc. today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
-
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
4/10/2024
Excision BioTherapeutics, Inc. today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.
-
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
4/10/2024
Blacksmith Medicines, Inc. (Blacksmith) today announced preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.
-
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
4/10/2024
Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.
-
Genomics Market Size To Hit USD 157.47 Billion By 2033
4/9/2024
The global genomics market size was valued at USD 33.90 billion in 2023 and is poised to grow from USD 39.53 billion in 2024 to USD 157.47 billion by 2033, growing at a CAGR of 16.6% in the forecast period (2024-2033).
-
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
4/9/2024
Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
-
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
4/8/2024
TScan Therapeutics, Inc. today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer.
-
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
4/8/2024
Actuate Therapeutics, Inc. announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.
-
Metagenomi to Present at Upcoming Scientific Meetings
4/8/2024
Metagenomi, Inc. today announced that two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.